News : kyowa hakko kirin

Uppsala, Sweden, August 27, 2010 – Orexo AB (STO: ORX) announces today that its partner Kyowa Hakko Kirin Co, Ltd. has decided to conduct additional clinical trials on the cancer pain drug KW-2246 (Orexo’s sublingual fentanyl product Abstral®).

An application for production and sale in Japan of KW-2246 as a treatment for breakthrough pain in cancer patients was made on February 24, 2010. However, following...

Uppsala, May 18, 2010 – Orexo AB (STO: ORX) today confirms that its partner, ProStrakan Group plc (LSE: PSK) has announced that AbstralTM continues to show strong sales development in 2010.

AbstralTM was launched across Europe during the course of 2009 and ProStrakan reported sales of £5.8 million in its first year on the market. In the first four months of 2010 AbstralTM has already recorded sales of £5.0 million....

Uppsala, February 17, 2010

Orexo AB (publ) –
Year-end Report January–December 2009



Key events during the year
• Net revenues totaled MSEK 236.1 (233.3).
• The loss after tax was MSEK 98.1 (loss: 103.1).
• The loss per share amounted to a loss of SEK 4.32 (loss: 4.77).
• Cash and cash equivalents at year-end totaled MSEK 87.4 (188.2).
• Abstral was launched in UK, Germany, France, Spain and Greece.
• In March,...

Uppsala, February 2, 2010 – Orexo AB (STO: ORX) announces today that its partner Kyowa Hakko Kirin Co., Ltd. has entered a joint distribution agreement for the cancer pain drug KW-2246 (Orexo’s sublingual fentanyl product) with the pharmaceutical company Hisamitsu Pharmaceutical Co., Inc.

Kyowa Hakko Kirin is responsible for the approval process for the product in Japan and under the terms of the agreement, KW-2246...

Orexo’s partner in Japan, Kyowa Hakko Kirin, has obtained positive phase III results in Japan for KW-2246, which is approved for the treatment of breakthrough pain in cancer patients and marketed under the brand AbstralTM in Europe. Kyowa Hakko Kirin will now proceed with preparations for a new-drug application for KW-2246 in Japan for use in continuous pain management of acute cancer pain (breakthrough pain)....